ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0906

Patients with Seronegative Rheumatoid Arthritis Have a Different Ultrasound-assessed Joint Disease Phenotype Than Seropositive Patients

Natalia Carbonell-Bobadilla1, Carina Soto-Fajardo2, Luis M Amezcua-Guerra3, Ana Beatriz Batres Marroquin4, Ana Cristina Medina5, Tania Vargas3, Adrián Hernández-Diazcouder3, Valentín Jiménez-Rojas3, Carlos Pineda5 and Luis H Silveira6, 1National Institute of Cardiology Ignacio Chávez, Ciudad de México, Mexico, 2Instituto Nacional de Rehabilitacion "Luis Guillermo Ibarra Ibarra", Ciudad de México, Mexico, 3Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico, 4Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Ciudad de México, Mexico, 5Instituto Nacional de Rehabilitacion, Ciudad de México, Mexico, 6Instituto Nacional de Cardiología, Ciudad de México, Mexico

Meeting: ACR Convergence 2022

Keywords: Anti-citrullinated Protein Autoantibodies (ACPAs), OMERACT, rheumatoid arthritis, Rheumatoid Factor, Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Diagnosis, Manifestations, and Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Seronegative rheumatoid arthritis (SNRA) tends to be less severe in its presentation and evolution than seropositive rheumatoid arthritis(SPRA), but controversy exists because there have been studies that show no differences between them.

The present study was aimed to evaluate if SNRA patients show lesser clinical severity, cardiovascular risk and morphostructural abnormalities assessed by US than SPRA patients.

Methods: Patients were enrolled as SNRA or SPRA, according to their RF and ACPA status.The degree of disease activity was established by DAS28-PCR 3 elements, Clinical disease activity index(CDAI) and Simple disease activity index(SDAI) .The cardiovascular risk scores Framingham 10-years risk, Reynolds, American College of Cardiology /American Heart Heart Association (ACC/AHA), and QRISK 3 were calculated.

US examinations were performed using MyLab7 (Esaote Biomedica, Genoa, Italy) equipped with a 6- to 18-MHzbroadband linear transducer. The images were scored for synovitis in Grey-Scale (GS) and Power Doppler (PD) according to the EULAR-OMERACT score system.

Results: Between 2019 and 2022, 114 patients were enrolled. 92 were women (n=65 SPRA 76% and n=27 SNRA 93%; p= 0.050). The age was 54 ± 13 IQR in ARSP and 63 ± 9 IQR in SNRA; p= < 0.001. The age of disease onset was 43 ± 14 IQR in SPRA and 54 ± 11 IQR in SNRA; p= < 0.001.

The treatment between patients had significative differences in the use of SSZ, CS , and in the median of the dose used in SPRA compared with SNRA.

Patients with SPRA had a higher proportion of synovitis in the right 2MCP joint (71 vs 38% p=0.008) and in the left ankle (29 vs 5%, p=0. 026). We also find in the right knee a higher proportion of patients with SNRA with grade >2 synovitis (52 vs 23%, p=0.023). In PD we found differences in the right 2MCP joint (49 vs 9% p=0.002), left 2MCP joint (35 vs 10%, p=0.03); and right 3MCP joint (39 vs 14%, p=0.043). We also found a higher proportion of patients with SNRA with PD in the left knee (33 vs 10% p=0.019). Patients with SPRA had a higher proportion of erosions in all sites evaluated (9 vs 1%, p< 0.001).

Conclusion: We found in our study that SNRA has a different phenotype compared to SPRA. It expresses later in life, with lesser need of combination therapy and with greater glucocorticoid dosage than seropositive patients. By US assessment, SPRA patients had a higher proportion of synovitis in the right 2MCP joint and in the left ankle and higher proportion of erosions.SNRA patients had a higher proportion of synovitis in the knee. Surprisingly, we did not find differences between groups in clinical assessment and cardiovascular 10 years risk scores.

Supporting image 1

Table 1. Clinical and laboratory features of patients with rheumatoid arthritis.

Supporting image 2


Disclosures: N. Carbonell-Bobadilla, None; C. Soto-Fajardo, None; L. Amezcua-Guerra, None; A. Batres Marroquin, None; A. Medina, None; T. Vargas, None; A. Hernández-Diazcouder, None; V. Jiménez-Rojas, None; C. Pineda, None; L. Silveira, None.

To cite this abstract in AMA style:

Carbonell-Bobadilla N, Soto-Fajardo C, Amezcua-Guerra L, Batres Marroquin A, Medina A, Vargas T, Hernández-Diazcouder A, Jiménez-Rojas V, Pineda C, Silveira L. Patients with Seronegative Rheumatoid Arthritis Have a Different Ultrasound-assessed Joint Disease Phenotype Than Seropositive Patients [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/patients-with-seronegative-rheumatoid-arthritis-have-a-different-ultrasound-assessed-joint-disease-phenotype-than-seropositive-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patients-with-seronegative-rheumatoid-arthritis-have-a-different-ultrasound-assessed-joint-disease-phenotype-than-seropositive-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology